GREENWICH LIFESCIENCES INC (GLSI)
Health Care · Cancer immunotherapy / breast cancer · NASDAQ
Greenwich LifeSciences develops GLSI-100, an immunotherapy combining a HER2/neu-targeting peptide and GM-CSF to prevent breast cancer recurrence after surgery.
What GREENWICH LIFESCIENCES INC does
Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy designed to prevent recurrence of breast cancer in patients with residual disease or high-risk pathologic complete response following surgery. The drug combines GP2 (a HER2/neu transmembrane peptide that elicits a targeted immune response) with GM-CSF (an FDA-approved immunoadjuvant). The company is currently conducting the Phase III Flamingo-01 trial and expanding it globally with up to 150 planned sites, including sites in Europe. The company has no revenue, negative cash flow, and substantial going concern doubts but has been raising capital through equity offerings.
Themes: Breast cancer immunotherapy, HER2/neu-targeted therapy, Cancer recurrence prevention, Personalized cancer immunotherapy
Fundamentals
- Price$17.58 as of 2026-08-24 close
- Market cap$258M as of 2026-08-24
- 1-year return+44.3% 2025-08-22 close $12.18 → 2026-08-24 close $17.58
- P/En/a earnings data not available
- ROE-941.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.58 as of 2026-08-24
- Last reported earningsn/a no earnings announcement (Form 8-K, Item 2.02) has been filed in our data yet
How GLSI compares in its sector
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How GREENWICH LIFESCIENCES INC looks technically
GREENWICH LIFESCIENCES INC (GLSI) is trading 13.8% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 12 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2026-07-16, pushing above its recent trading range. It is 48.4% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 13.8% below its 200-day average, the long-term trend line — a long-term downtrend | -13.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $17.92 | $17.92 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $20.40 | $20.40 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 31 calendar days ago — the swings before that are what the structure reading is measured on | 31 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 17.96. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 12 trading days ago — a "death cross", a bearish long-term signal | 12 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 18.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30) | 55.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($14.19 to $18.17) — its "stochastic" reading is 85 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 85.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 16 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $34.10 | $34.10 |
|---|---|---|
| From the 52-week high | it is 48.4% below its 52-week high (its highest price of the past year) | -48.5% |
| Above the 52-week low | it is 126.0% above its 52-week low (its lowest price of the past year) | +126.0% |
| Below the 52-week high | it is 48.4% below its highest point of the past year | 48.5% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-07-16, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 19 trading days ago | 19 sessions |
| All-time high | its highest closing price on record is $69.77 (set on 2021-04-09) | $69.77 |
| Given back of the 52-week move | over the past year its closes ranged ($7.85 to $33.56), and it has given back close to two thirds of its rise from last year’s low — 62% of it. Chart-watchers call 61.8%-65% given back the "golden pocket", and this is inside it — for this company that is $16.85 to $17.67. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 62.2% |
| From the all-time high | it is 74.8% below its all-time high | -74.8% |
| Nearest price level | it is trading 6.1% above a support level at $16.51 — a price it turned at twice since 2024-09-09, most recently on 2026-06-25. Since 2024-08-26 it has 14 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -6.1% |
| All-time low | its lowest closing price on record is $6.82 (set on 2022-06-13) | $6.82 |
| Above the all-time low | it is 157.6% above its all-time low | +157.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 75% of it) | 75th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.58 between its high and its low — about 9.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.58 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $12.31 and $18.43 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $12.31 – $15.37 – $18.43 |
| Typical daily range (% of price) | its price moves about 9.0% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 9.0% |
| Stretch from the 200-day average | it is trading 1.8 daily ranges below its 200-day average price (13.8% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.59× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Price gaps
3
| Gap at the open | it opened on 2026-08-24 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Open gap | it gapped 5.6% above the previous close 1 session ago and has not traded back through the level it left behind at 15.31 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +5.5% |
| Gap filled | a 2.6% gap up opened on 2026-08-19 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 3 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +14.83% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 32.1 percentage points (the stock gained 35.4% while the market gained 3.3%) | +32.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 38.8 percentage points (the stock lost 36.4% while the market gained 2.4%) | -38.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 40.4 percentage points (the stock lost 29.3% while the market gained 11.1%) | -40.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 26.0 percentage points (the stock gained 44.3% while the market gained 18.3%) | +26.0% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 10% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 18.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -10.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 27% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $23.94 — a volume-weighted average of daily closes over 156 sessions, not a true tick-by-tick VWAP. | -26.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-06-01 (its 10-K), so the typical buyer over that stretch is under water. That average is $18.39 — a volume-weighted average of daily closes over 56 sessions, not a true tick-by-tick VWAP. | -4.4% |
Price levels it has turned at before
GLSI last closed at $17.58 on 2026-08-24. Since 2024-08-26 it has turned at 14 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $16.51 | Support | 6.1% below the last close | turned there twice · 2024-09-09 to 2026-06-25 |
| $15.48 | Support | 11.9% below the last close | turned there twice · 2024-09-25 to 2024-12-02 |
| $14.54 | Support | 17.3% below the last close | turned there four times · 2024-10-16 to 2025-01-27 |
| $21.67 | Resistance | 23.3% above the last close | turned there twice · 2026-02-23 to 2026-07-16 |
| $29.05 | Resistance | 65.2% above the last close | turned there twice · 2026-03-04 to 2026-05-15 |
| $30.14 | Resistance | 71.5% above the last close | turned there three times · 2026-03-17 to 2026-06-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $17.96.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $14.68 and $17.11 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $12.51.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$57.00 range $45.00 – $69.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Clinical development risk: Phase III trial (Flamingo-01) may not achieve primary efficacy endpoints required for regulatory approval","Going concern risk: Company has cumulative losses of $92.8M, negative operating cash flows, zero revenue, and substantial doubt about ability to continue operations within one year without additional capital","Supply chain dependency: Exclusive reliance on single manufacturer for GM-CSF component; component only FDA-approved in US and availability in other countries subject to regulatory uncertainty"]
What changed in the latest 10-Q
AI-assisted comparison of GLSI's 10-Q filed 2026-06-04 against the prior one filed 2025-11-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Form 10-K for year ended December 31, 2025 (newer filing, filed 2026-06-04)
- Net losses of $19.4 million and $17.4 million for years ended December 31, 2025 and 2024 (newer filing, filed 2026-06-04)
- Net losses of $5.7 million and $2.7 million for three months ended March 31, 2026 and 2025 (newer filing, filed 2026-06-04)
- Results of Operations for Three Months Ended March 31, 2026 and 2025 section (newer filing, filed 2026-06-04)
- R&D expenses increased $2,936,416 (129%) to $5,207,564 for Q1 2026 vs Q1 2025 (newer filing, filed 2026-06-04)
- G&A expenses increased $20,588 (4%) to $518,190 for Q1 2026 vs Q1 2025 (newer filing, filed 2026-06-04)
- Cash position of $10,505,435 as of March 31, 2026 (newer filing, filed 2026-06-04)
- Net losses of $5,657,137 and $2,744,780 for three month periods ended March 31, 2026 and 2025 (newer filing, filed 2026-06-04)
- Net cash used in operating activities of $4,702,498 for Q1 2026 and $1,834,454 for Q1 2025 (newer filing, filed 2026-06-04)
- ATM offerings information: 367,547 shares at $25.33 per share for gross proceeds of $9,309,18 (partial, newer filing, filed 2026-06-04)
- Removed:
- Reference to Form 10-K for year ended December 31, 2024 with filing date April 15, 2025 (older filing, filed 2025-11-14)
- Net losses of $15.8 million and $8.9 million for years ended December 31, 2024 and 2023 (older filing, filed 2025-11-14)
- Net losses of $11.4 million and $7.7 million for nine months ended September 30, 2025 and 2024 (older filing, filed 2025-11-14)
- Results of Operations for Three Months Ended September 30, 2025 and 2024 section (older filing, filed 2025-11-14)
- Results of Operations for Nine Months Ended September 30, 2025 and 2024 section (older filing, filed 2025-11-14)
- R&D expenses increased $1,229,536 (54%) to $3,521,576 for Q3 2025 vs Q3 2024 (older filing, filed 2025-11-14)
- G&A expenses increased $216,055 (49%) to $653,066 for Q3 2025 vs Q3 2024 (older filing, filed 2025-11-14)
- R&D expenses increased $2,836,178 (42%) to $9,630,604 for nine months ended September 30, 2025 vs 2024 (older filing, filed 2025-11-14)
- G&A expenses increased $739,093 (65%) to $1,872,323 for nine months ended September 30, 2025 vs 2024 (older filing, filed 2025-11-14)
- Cash position of $3,806,978 as of September 30, 2025 (older filing, filed 2025-11-14)
- Mention of options grant as driver of R&D expense increases (older filing, filed 2025-11-14)
- Mention of options grant to board of directors as driver of G&A increases (older filing, filed 2025-11-14)
- Reworded:
- Comparison period changed from nine months ended September 30 to three months ended March 31 (newer filing, filed 2026-06-04)
- R&D expense increase driver changed from 'options grant and increase in clinical expenses' to 'increase in accounts payable for clinical trial expenses' (newer filing, filed 2026-06-04)
- G&A expense increase driver changed from 'options grant to employees, management, and board' to only mentioning the increase amount without specific attribution (newer filing, filed 2026-06-04)
- Cash flow analysis now references 'increase in clinical trial expenses' rather than specifying options grants (newer filing, filed 2026-06-04)
- Notes:
- The newer filing's Financing Activities section appears truncated at 'for gross proceeds of $9,309,18' and does not contain complete information
- The older filing's Liquidity and Capital Resources section also appears truncated at the end, limiting full comparison of that section
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
5 open-market purchases and 0 open-market sales by insiders in the last 90 days.
- Last 30 days3 buys ($49985) · 0 sells — 1 buying insider
- Last 90 days5 buys ($97003) · 0 sells — 1 buying insider
- Last 180 days5 buys ($97003) · 0 sells — 1 buying insider
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-29. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about GLSI's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding GLSI as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 571,842
- Reported value $13,735,655
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
GLSI had 1,541,345 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
GLSI had 10.5% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.18 days to cover at the same settlement.
- Reported short interest (shares) 1,541,345
- Short interest (% of shares outstanding) 10.5%
- Prior settlement (shares) 1,467,739
- Reported change 5.01%
- Days to cover (reported) 7.18
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Roche/Genentech (HER2-targeted therapies including Herceptin)
- Pfizer (HER2-directed therapies)
- AstraZeneca (breast cancer immunotherapies)
- Merck (cancer immunotherapy platform)
- Bristol Myers Squibb (checkpoint inhibitors and cancer immunotherapy)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GLSI vs…
Frequently asked questions
What does GREENWICH LIFESCIENCES INC (GLSI) do?
Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy designed to prevent recurrence of breast cancer in patients with residual disease or high-risk pathologic complete response following surgery. The drug combines GP2 (a HER2/neu transmembrane peptide that elicits a targeted immune response) with GM-CSF (an FDA-approved immunoadjuvant).
What sector is GREENWICH LIFESCIENCES INC (GLSI) in?
GREENWICH LIFESCIENCES INC (GLSI) is classified in the Health Care sector. Its industry is Cancer immunotherapy / breast cancer. It trades on NASDAQ.
Who are GREENWICH LIFESCIENCES INC's (GLSI) competitors?
Notable peers of GREENWICH LIFESCIENCES INC (GLSI) include Roche/Genentech (HER2-targeted therapies including Herceptin), Pfizer (HER2-directed therapies), AstraZeneca (breast cancer immunotherapies), Merck (cancer immunotherapy platform) and Bristol Myers Squibb (checkpoint inhibitors and cancer immunotherapy). This peer set is informational only — not financial advice.
Is GREENWICH LIFESCIENCES INC (GLSI) overbought or oversold right now?
GREENWICH LIFESCIENCES INC (GLSI) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 56, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GLSI come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.